Company: HURA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047921
Chunk: 425

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-03-31
Form: 10-K
Item: Item 8
Chunk 425
---
 (1,117,497
    )

    -

    Payment of net liabilities assumed in reverse recapitalization

    (796,912
    )

    -

    Net cash flows from financing activities

    29,772,693

    2,660,249

    Net change in cash and cash equivalents

    8,992,146

    (10,587,486
    )

    Cash and cash equivalents at the beginning of the year

    3,665,032

    14,252,518

    Cash and cash equivalents at the end of the year
     
    $
    12,657,178

    $
    3,665,032

    Supplemental non-cash activity

    Shares issued and reserved for asset acquisition
     
    $
    -

    $
    15,000,000

    Right-of-use asset recognized in exchange for operating lease obligations

    318,722

    -

    Debt issuance costs not yet paid

    -

    242,530

    Net liabilities assumed in reverse recapitalization not yet paid

    550,000

    -

    Merger transaction costs not yet paid

    500,000

    -

    Derivative liability associated with make-whole premium

    2,402,228

    137,000

    Fair value of warrants associated with convertible notes payable

    6,520,056

    -

    Deemed dividend on warrant modifications

    965,177

    -

    Issuance of common stock for placement agent fees

    443,560

    -

    Preferred Series A cash dividend not yet paid

    2,089

    -

    Fair value of contingent value rights associated with reverse recapitalization

    5,127,927

    -

    Fair value of warrants issued to financial advisor

    1,642,867

    -

    Shares issued upon settlement of convertible notes

    27,742,649

    -

F-9

TUHURA BIOSCIENSES, INC AND SUBSIDIARIESNotes to the consolidated financial statementsFor the years ended December 31, 2024, and 2023